Glenmark Pharmaceuticals S.A. is a R&D centre focused on biologics established in 2004. It is a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (India). The biologics research centre focuses on discovery and development of novel biological entities, comprising of monoclonal antibody products targeted towards oncology and inflammation disease areas. The unit has all capabilities required to develop antibody products and take them rapidly from early discovery to clinical phase testing.
Contact
Street: Chemin de la Combeta 5
ZIP: 2300
City: La Chaux-de-Fonds
Phone: +41 32 729 35 50
Fax: +41 32 729 35 60
Homepage: http://www.glenmarkpharma.com
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment…
Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through…
Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis…
See our Cookie Privacy Policy Here
